DK1681353T3 - Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35 - Google Patents

Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35

Info

Publication number: DK1681353T3
Authority: DK; Denmark
Prior art keywords: adenovirus; serotypes; tropism; proteins; gene transfer
Prior art date: 1999-05-17

Application number

DK05077719T

Other languages

English (en)

Inventor

Abraham Bout

Ronald Vogels

Menzo Jans Emco Havenga

Original Assignee

Crucell Holland Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-17

Filing date

2000-05-16

Publication date

2010-01-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1681353(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-16 Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv

2010-01-04 Application granted granted Critical

2010-01-04 Publication of DK1681353T3 publication Critical patent/DK1681353T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Virology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK05077719T 1999-05-17 2000-05-16 Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35 DK1681353T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99201545		1999-05-17
PCT/NL2000/000325 WO2000070071A1 (en)	1999-05-17	2000-05-16	Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35

Publications (1)

Publication Number	Publication Date
DK1681353T3 true DK1681353T3 (da)	2010-01-04

Family

ID=8240209

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
DK05077719T DK1681353T3 (da)	1999-05-17	2000-05-16	Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
DK04077434T DK1550722T3 (da)	1999-05-17	2000-05-16	Rekombinant human adenovirus serotype 35
DK07106044.6T DK1816204T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus af Ad26-serotypen
DK07106036.2T DK1818408T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus af serotypen Ad11
DK07106054.5T DK1816205T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus på grundlag af serotypen Ad48
DK00201738.2T DK1054064T4 (da)	1999-05-17	2000-05-16	Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
DK04077434T DK1550722T3 (da)	1999-05-17	2000-05-16	Rekombinant human adenovirus serotype 35
DK07106044.6T DK1816204T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus af Ad26-serotypen
DK07106036.2T DK1818408T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus af serotypen Ad11
DK07106054.5T DK1816205T3 (da)	1999-05-17	2000-05-16	Rekombinant adenovirus på grundlag af serotypen Ad48
DK00201738.2T DK1054064T4 (da)	1999-05-17	2000-05-16	Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35

Country Status (14)

Country	Link
EP (6)	EP1818408B1 (da)
JP (2)	JP4843145B2 (da)
KR (1)	KR100741247B1 (da)
AT (6)	ATE485382T1 (da)
AU (1)	AU777041B2 (da)
CA (1)	CA2372655C (da)
CY (4)	CY1106762T1 (da)
DE (4)	DE60035229T2 (da)
DK (6)	DK1681353T3 (da)
ES (5)	ES2231103T5 (da)
IL (3)	IL146479A0 (da)
NZ (1)	NZ515582A (da)
PT (5)	PT1816205E (da)
WO (1)	WO2000070071A1 (da)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6783980B2 (en)	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
EP0833934B2 (en)	1995-06-15	2012-08-15	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030017138A1 (en)	1998-07-08	2003-01-23	Menzo Havenga	Chimeric adenoviruses
US6929946B1 (en)	1998-11-20	2005-08-16	Crucell Holland B.V.	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en)	1999-03-04	2005-03-22	Crucell Holland B.V.	Means and methods for fibroblast-like or macrophage-like cell transduction
US6492169B1 (en)	1999-05-18	2002-12-10	Crucell Holland, B.V.	Complementing cell lines
US6913922B1 (en)	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
US7094398B1 (en)	1999-06-01	2006-08-22	University Of Washington	Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6558948B1 (en)	1999-11-23	2003-05-06	Stefan Kochanek	Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1191105A1 (en) *	2000-09-25	2002-03-27	Galapagos Genomics B.V.	Gene delivery vectors provided with a tissue tropism for T-lymphocytes
WO2001092547A2 (en)	2000-05-31	2001-12-06	University Of Saskatchewan	Modified bovine adenovirus having altered tropism
NZ524743A (en) *	2000-09-20	2004-07-30	Crucell Holland B	Gene delivery vectors provided with a tissue tropism for dendritic cells provided by a viral capsid protein
DE60138403D1 (de)	2000-09-26	2009-05-28	Crucell Holland Bv	Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
WO2002029073A2 (en) *	2000-10-06	2002-04-11	Crucell Holland B.V.	Gene delivery vectors for stem cells
EP1195440A1 (en) *	2000-10-06	2002-04-10	Introgene B.V.	Gene delivery vectors for stem cells
EP1348030B1 (en)	2001-01-04	2009-11-25	Wadell, Göran	Viral vector for gene therapy
CA2439185A1 (en)	2001-02-23	2002-09-06	Novartis Ag	Vector constructs
EP1516055A4 (en) *	2002-01-24	2007-08-08	Scripps Research Inst	FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
AU2003271738C1 (en)	2002-04-25	2008-04-17	Crucell Holland B.V.	Stable adenoviral vectors and methods for propagation thereof
PT1497438E (pt) *	2002-04-25	2010-02-04	Crucell Holland Bv	Meios e métodos para a produção de vectores de adenovírus
JP4237449B2 (ja) *	2002-06-05	2009-03-11	国立医薬品食品衛生研究所長	アデノウィルスベクター
US20080153083A1 (en)	2003-10-23	2008-06-26	Crucell Holland B.V.	Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en)	2002-10-23	2005-07-20	Crucell Holland B.V.	New settings for recombinant adenoviral-based vaccines
NZ539813A (en)	2002-12-17	2008-04-30	Crucell Holland Bv	A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
EP1646717A4 (en) *	2003-07-18	2006-12-20	Onyx Pharma Inc	ADENOVIRAL VECTORS OF SUB-GROUP B FOR THE TREATMENT OF DISEASES
DE602005015332D1 (de)	2004-02-23	2009-08-20	Crucell Holland Bv	Verfahren zur Reinigung von Viren
CN1972958B (zh) *	2004-04-12	2013-01-23	美国政府卫生与公共服务部	应用腺病毒载体诱导免疫应答的方法
KR101169109B1 (ko)	2004-05-26	2012-07-26	싸이오서스 테라퓨틱스 엘티디.	암 치료에 사용하기 위한 키메릭 아데노바이러스
BRPI0516048A (pt)	2004-10-13	2008-08-19	Crucell Holland B V E Beth Isr	batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c
SG159554A1 (en)	2004-11-16	2010-03-30	Crucell Holland Bv	Multivalent vaccines comprising recombinant viral vectors
US8574595B2 (en)	2005-04-11	2013-11-05	Crucell Holland B.V.	Virus purification using ultrafiltration
EP1907536B1 (en)	2005-07-22	2010-04-07	Crucell Holland B.V.	Cell line for producing coronaviruses
US20100143302A1 (en) *	2006-03-16	2010-06-10	Crucell Holland B.V.	Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
DK2350268T3 (da)	2008-11-03	2015-03-23	Crucell Holland Bv	Fremgangsmåde til produktion af adenovirusvektorer
WO2011015656A2 (en)	2009-08-07	2011-02-10	Transgene Sa	Composition for treating hbv infection
US20120315696A1 (en) *	2010-02-15	2012-12-13	Alfred Luitjens	METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
EP2536829B1 (en)	2010-02-15	2016-04-06	Crucell Holland B.V.	Method for the production of Ad26 adenoviral vectors
EP2618838A1 (en)	2010-09-20	2013-07-31	Crucell Holland B.V.	Therapeutic vaccination against active tuberculosis
WO2012041669A1 (en)	2010-09-27	2012-04-05	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
CN102260712B (zh) *	2011-05-31	2013-10-02	北京锤特生物科技有限公司	溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
JP5770952B2 (ja)	2012-03-12	2015-08-26	クルセルホランドベーヴェー	改変末端を有する組換えアデノウイルスのバッチ
CA2867955C (en)	2012-03-22	2023-02-07	Crucell Holland B.V.	Vaccine against rsv
US9119813B2 (en)	2012-03-22	2015-09-01	Crucell Holland B.V.	Vaccine against RSV
JP6162224B2 (ja)	2012-05-24	2017-07-12	クルセルホランドベーヴェー	血管組織の形質導入のためのアデノウイルスベクター
WO2014009433A1 (en)	2012-07-10	2014-01-16	Transgene Sa	Mycobacterium resuscitation promoting factor for use as adjuvant
CN104640564B (zh)	2012-07-10	2020-08-04	特兰斯吉恩股份有限公司	分枝杆菌抗原疫苗
CN105051198A (zh)	2012-11-16	2015-11-11	貝丝以色列女执事医疗中心	重组腺病毒及其用途
CA3115891A1 (en)	2013-03-14	2014-09-25	Salk Institute For Biological Studies	Oncolytic adenovirus compositions
DK2988780T3 (da)	2013-04-25	2019-04-08	Janssen Vaccines & Prevention Bv	Stabiliserede opløselige rsv-f-præfusionspolypeptider
CN105408348B (zh)	2013-06-17	2021-07-06	扬森疫苗与预防公司	稳定化的可溶性融合前rsv f多肽
TR201802728T4 (tr)	2013-10-25	2018-03-21	Psioxus Therapeutics Ltd	Heterolog genlerle donatılmış onkolitik adenovirüsler.
BR112016015936A2 (pt)	2014-01-09	2017-09-19	Transgene Sa	Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição
BR112017004202A2 (pt)	2014-09-03	2019-09-03	Bavarian Nordic As	composições para intensificar respostas imunes e seus usos
WO2016036955A1 (en)	2014-09-03	2016-03-10	Bavarian Nordic A/S	Methods and compositions for inducing protective immunity against filovirus infection
MY175620A (en)	2014-09-26	2020-07-02	Beth Israel Deaconess Medical Ct Inc	Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
EP3215187B1 (en)	2014-11-04	2018-08-29	Janssen Vaccines & Prevention B.V.	Therapeutic hpv16 vaccines
US10570417B2 (en)	2015-04-14	2020-02-25	Janssen Vaccines & Prevention B.V.	Recombinant adenovirus expressing two transgenes with a bidirectional promoter
SMT202000222T1 (it)	2015-04-30	2020-05-08	Psioxus Therapeutics Ltd	Adenovirus oncolitico che codifica per una proteina b7
AU2016289492B2 (en)	2015-07-07	2022-08-11	Janssen Vaccines & Prevention B.V.	Vaccine against RSV
EP3319634B1 (en)	2015-07-07	2019-08-21	Janssen Vaccines & Prevention B.V.	Stabilized soluble pre-fusion rsv f polypeptides
JP6470872B2 (ja)	2015-08-20	2019-02-13	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	治療用ｈｐｖ１８ワクチン
MA44059B1 (fr)	2015-12-15	2019-11-29	Janssen Vaccines & Prevention Bv	Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation
SG11201805137XA (en)	2015-12-17	2018-07-30	Psioxus Therapeutics Ltd	Virus encoding an anti-tcr-complex antibody or fragment
KR20220163505A (ko)	2016-02-23	2022-12-09	솔크 인스티튜트 포 바이올로지칼 스터디즈	바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
AU2017222568B2 (en)	2016-02-23	2020-09-10	Salk Institute For Biological Studies	High throughput assay for measuring adenovirus replication kinetics
JP7088841B2 (ja)	2016-04-05	2022-06-21	ヤンセンファッシンズアンドプリベンションベーフェー	安定化された可溶性融合前ｒｓｖｆタンパク質
JP7233928B2 (ja)	2016-04-05	2023-03-07	ヤンセンファッシンズアンドプリベンションベーフェー	Ｒｓｖに対するワクチン
JP7053491B2 (ja)	2016-05-02	2022-04-12	ヤンセンファッシンズアンドプリベンションベーフェー	治療用ｈｐｖワクチン組み合わせ
WO2017207480A1 (en)	2016-05-30	2017-12-07	Janssen Vaccines & Prevention B.V.	Stabilized pre-fusion rsv f proteins
US10273268B2 (en)	2016-06-16	2019-04-30	Janssen Vaccines & Prevention B.V.	HIV vaccine formulation
US11001858B2 (en)	2016-06-20	2021-05-11	Janssen Vaccines & Prevention B.V.	Potent and balanced bidirectional promoter
WO2018011196A1 (en)	2016-07-14	2018-01-18	Janssen Vaccines & Prevention B.V.	Hpv vaccines
WO2018011768A1 (en)	2016-07-15	2018-01-18	Janssen Vaccines And Prevention B.V.	Methods and compositions for inducing protective immunity against a marburg virus infection
EP3484505A1 (en)	2016-07-15	2019-05-22	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against a marburg virus infection
IL303187A (en)	2016-08-29	2023-07-01	Akamis Bio Ltd	Adenovirus armed with bispecific t cell activator
GB201713765D0 (en)	2017-08-28	2017-10-11	Psioxus Therapeutics Ltd	Modified adenovirus
JP2019536468A (ja)	2016-12-12	2019-12-19	ソークインスティテュートフォーバイオロジカルスタディーズ	腫瘍を標的にする合成アデノウイルスおよびその使用
JP6721797B2 (ja)	2017-02-09	2020-07-15	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	異種遺伝子発現のための強力で短いプロモーター
US11173204B2 (en)	2017-04-06	2021-11-16	Janssen Vaccines & Prevention B.V.	MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
US11229692B2 (en)	2017-05-17	2022-01-25	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against RSV infection
WO2018210871A1 (en)	2017-05-17	2018-11-22	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against rsv infection
US11229693B2 (en)	2017-06-15	2022-01-25	Janssen Vaccines & Prevention B.V.	Poxvirus vectors encoding HIV antigens, and methods of use thereof
EP3681533A1 (en)	2017-09-15	2020-07-22	Janssen Vaccines & Prevention B.V.	Method for the safe induction of immunity against rsv
EP3713599A1 (en)	2017-11-20	2020-09-30	Janssen Pharmaceuticals, Inc.	Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
WO2019118480A1 (en)	2017-12-11	2019-06-20	Beth Israel Deaconess Medical Center, Inc.	Recombinant adenoviruses and uses thereof
CN111741766A (zh)	2017-12-19	2020-10-02	杨森科学爱尔兰无限公司	用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
EP3810277A1 (en)	2018-07-20	2021-04-28	Janssen Vaccines & Prevention B.V.	Recombinant adenoviral vector expressing zika antigen with improved productivity
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
US20220273787A1 (en)	2019-05-15	2022-09-01	Janssen Vaccines & Prevention B.V.	Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CA3140234A1 (en)	2019-05-15	2020-11-19	Janssen Vaccines & Prevention B.V.	Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
JP7630507B2 (ja)	2019-11-18	2025-02-17	ヤンセンバイオテツク，インコーポレーテツド	変異型ｃａｌｒ及びｊａｋ２に基づくワクチン並びにこれらの使用
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
CN111337042B (zh) *	2020-03-13	2021-11-02	湖北大学	一种车辆路径规划方法及系统
EP4135757A1 (en)	2020-04-13	2023-02-22	Janssen Biotech, Inc.	Psma and steap1 vaccines and their uses
EP4175664A2 (en)	2020-07-06	2023-05-10	Janssen Biotech, Inc.	Prostate neoantigens and their uses
WO2022009049A1 (en)	2020-07-06	2022-01-13	Janssen Biotech, Inc.	Prostate neoantigens and their uses
EP4176087A1 (en)	2020-07-06	2023-05-10	Janssen Biotech, Inc.	A method for determining responsiveness to prostate cancer treatment
CN116367854A (zh)	2020-07-08	2023-06-30	杨森科学爱尔兰无限公司	针对hbv的rna复制子疫苗
GB202013940D0 (en)	2020-09-04	2020-10-21	Synpromics Ltd	Regulatory nucleic acid sequences
WO2022076556A2 (en)	2020-10-07	2022-04-14	Asklepios Biopharmaceutical, Inc.	Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
WO2022140759A2 (en)	2020-12-23	2022-06-30	Janssen Biotech, Inc.	Neoantigen peptide mimics
WO2023198815A1 (en)	2022-04-14	2023-10-19	Janssen Vaccines & Prevention B.V.	Sequential administration of adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2725726B1 (fr) *	1994-10-17	1997-01-03	Centre Nat Rech Scient	Vecteurs viraux et utilisation en therapie genique
US5856152A (en) *	1994-10-28	1999-01-05	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV vector and methods of use therefor
EP0833934B2 (en)	1995-06-15	2012-08-15	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) *	1995-10-02	1998-11-17	Cornell Research Foundation, Inc.	Non-group C adenoviral vectors
US5877011A (en) *	1996-11-20	1999-03-02	Genzyme Corporation	Chimeric adenoviral vectors
US6100086A (en) *	1997-04-14	2000-08-08	Genzyme Corporation	Transgene expression systems
CA2364499C (en) *	1999-03-04	2008-12-23	Introgene B.V.	Means and methods for fibroblast-like or macrophage-like cell transduction
AU2009254168A1 (en) *	2008-06-03	2009-12-10	Okairos Ag	A vaccine for the prevention and therapy of HCV infections

2000
- 2000-05-16 ES ES00201738T patent/ES2231103T5/es not_active Expired - Lifetime
- 2000-05-16 AU AU49547/00A patent/AU777041B2/en not_active Expired
- 2000-05-16 DK DK05077719T patent/DK1681353T3/da active
- 2000-05-16 WO PCT/NL2000/000325 patent/WO2000070071A1/en active Application Filing
- 2000-05-16 DK DK04077434T patent/DK1550722T3/da active
- 2000-05-16 DE DE60035229T patent/DE60035229T2/de not_active Expired - Lifetime
- 2000-05-16 DK DK07106044.6T patent/DK1816204T3/da active
- 2000-05-16 ES ES04077434T patent/ES2289426T3/es not_active Expired - Lifetime
- 2000-05-16 DE DE60045138T patent/DE60045138D1/de not_active Expired - Lifetime
- 2000-05-16 AT AT07106044T patent/ATE485382T1/de active
- 2000-05-16 EP EP07106036A patent/EP1818408B1/en not_active Expired - Lifetime
- 2000-05-16 EP EP07106044A patent/EP1816204B1/en not_active Expired - Lifetime
- 2000-05-16 DK DK07106036.2T patent/DK1818408T3/da active
- 2000-05-16 AT AT04077434T patent/ATE364707T1/de active
- 2000-05-16 IL IL14647988A patent/IL146479A0/xx unknown
- 2000-05-16 KR KR1020017014631A patent/KR100741247B1/ko not_active Expired - Lifetime
- 2000-05-16 PT PT07106054T patent/PT1816205E/pt unknown
- 2000-05-16 NZ NZ515582A patent/NZ515582A/en not_active IP Right Cessation
- 2000-05-16 CA CA2372655A patent/CA2372655C/en not_active Expired - Lifetime
- 2000-05-16 ES ES07106054T patent/ES2372824T3/es not_active Expired - Lifetime
- 2000-05-16 EP EP07106054A patent/EP1816205B1/en not_active Expired - Lifetime
- 2000-05-16 AT AT07106036T patent/ATE519855T1/de active
- 2000-05-16 AT AT05077719T patent/ATE445018T1/de not_active IP Right Cessation
- 2000-05-16 JP JP2000618477A patent/JP4843145B2/ja not_active Expired - Lifetime
- 2000-05-16 PT PT00201738T patent/PT1054064E/pt unknown
- 2000-05-16 AT AT00201738T patent/ATE278792T1/de active
- 2000-05-16 DK DK07106054.5T patent/DK1816205T3/da active
- 2000-05-16 EP EP00201738A patent/EP1054064B2/en not_active Expired - Lifetime
- 2000-05-16 PT PT04077434T patent/PT1550722E/pt unknown
- 2000-05-16 DE DE60043126T patent/DE60043126D1/de not_active Expired - Lifetime
- 2000-05-16 DK DK00201738.2T patent/DK1054064T4/da active
- 2000-05-16 ES ES07106036T patent/ES2372823T3/es not_active Expired - Lifetime
- 2000-05-16 AT AT07106054T patent/ATE519854T1/de active
- 2000-05-16 DE DE60014489T patent/DE60014489T3/de not_active Expired - Lifetime
- 2000-05-16 EP EP05077719A patent/EP1681353B1/en not_active Expired - Lifetime
- 2000-05-16 ES ES07106044T patent/ES2354578T3/es not_active Expired - Lifetime
- 2000-05-16 PT PT07106044T patent/PT1816204E/pt unknown
- 2000-05-16 PT PT07106036T patent/PT1818408E/pt unknown
- 2000-05-16 EP EP04077434A patent/EP1550722B1/en not_active Expired - Lifetime
2001
- 2001-11-13 IL IL146479A patent/IL146479A/en not_active IP Right Cessation
2007
- 2007-07-25 CY CY20071100996T patent/CY1106762T1/el unknown
2011
- 2011-01-10 CY CY20111100030T patent/CY1111494T1/el unknown
- 2011-07-14 JP JP2011156125A patent/JP5335037B2/ja not_active Expired - Lifetime
- 2011-08-02 IL IL214413A patent/IL214413A/en not_active IP Right Cessation
- 2011-11-07 CY CY20111101074T patent/CY1112008T1/el unknown
- 2011-11-07 CY CY20111101075T patent/CY1112189T1/el unknown

Also Published As

Publication number	Publication date
DK1054064T3 (da)	2005-01-10
EP1550722B1 (en)	2007-06-13
ATE519855T1 (de)	2011-08-15
DE60014489D1 (de)	2004-11-11
JP2002543846A (ja)	2002-12-24
PT1818408E (pt)	2011-11-15
DE60043126D1 (de)	2009-11-19
CA2372655A1 (en)	2000-11-23
EP1681353B1 (en)	2009-10-07
ES2231103T5 (es)	2010-04-15
EP1818408B1 (en)	2011-08-10
CY1112189T1 (el)	2015-12-09
EP1816204A1 (en)	2007-08-08
DK1816204T3 (da)	2011-01-24
ATE364707T1 (de)	2007-07-15
EP1816205A1 (en)	2007-08-08
ES2231103T3 (es)	2005-05-16
ATE519854T1 (de)	2011-08-15
EP1816204B1 (en)	2010-10-20
ATE445018T1 (de)	2009-10-15
ATE278792T1 (de)	2004-10-15
EP1681353A1 (en)	2006-07-19
ES2289426T3 (es)	2008-02-01
EP1818408A1 (en)	2007-08-15
WO2000070071A1 (en)	2000-11-23
PT1550722E (pt)	2007-09-25
EP1054064B1 (en)	2004-10-06
IL214413A0 (en)	2011-09-27
JP5335037B2 (ja)	2013-11-06
DE60045138D1 (de)	2010-12-02
DE60014489T3 (de)	2010-08-12
CY1111494T1 (el)	2015-08-05
DE60035229T2 (de)	2008-02-21
EP1816205B1 (en)	2011-08-10
IL214413A (en)	2014-04-30
CY1106762T1 (el)	2012-05-23
PT1816204E (pt)	2011-01-24
DE60035229D1 (de)	2007-07-26
EP1550722A1 (en)	2005-07-06
JP2011224014A (ja)	2011-11-10
IL146479A0 (en)	2002-07-25
ES2372824T3 (es)	2012-01-26
ES2372823T3 (es)	2012-01-26
NZ515582A (en)	2003-11-28
KR100741247B1 (ko)	2007-07-19
CA2372655C (en)	2011-11-15
DK1816205T3 (da)	2011-11-21
CY1112008T1 (el)	2015-11-04
DK1054064T4 (da)	2010-05-03
DK1550722T3 (da)	2007-10-08
ATE485382T1 (de)	2010-11-15
EP1054064A1 (en)	2000-11-22
JP4843145B2 (ja)	2011-12-21
AU777041B2 (en)	2004-09-30
PT1054064E (pt)	2005-02-28
ES2354578T3 (es)	2011-03-16
DK1818408T3 (da)	2011-10-17
KR20020028879A (ko)	2002-04-17
DE60014489T2 (de)	2005-11-24
PT1816205E (pt)	2011-11-15
AU4954700A (en)	2000-12-05
EP1054064B2 (en)	2009-12-16
IL146479A (en)	2011-12-29

Publication	Publication Date	Title
DK1681353T3 (da)	2010-01-04	Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
EE05538B1 (et)	2012-04-16	Interleukiin-18 seostuvad valgud, nende valmistamine ja kasutamine
EP1522588A3 (en)	2006-06-07	Accessory functions for use in recombinant AAV virion production
NZ336829A (en)	2001-03-30	Adenoviruses having altered hexon proteins which present epitopes that are not recognised by neutralizing antibodies to the unmodified adenovirus of another serotype
DE69233013D1 (de)	2003-05-22	Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
EP1015005A4 (en)	2002-10-16	GEN TRANSFER WITH THE AID OF MODIFIED FIBER PROTEINS WITH ADENOVIRUS
JP2002537816A5 (da)	2011-02-24
WO2000073478A3 (en)	2001-07-05	Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
WO2002018948A3 (en)	2003-08-28	Differentially expressed epitopes and uses thereof
FI20002392L (fi)	2002-05-01	Menetelmä ja valmiste asetaldehydin sitomiseksi, mahalaukussa ja paksusuolessa
NO20022898L (no)	2002-12-30	Sammensetning for cellespesifikk transfer av aktive substanser
NO20020367L (no)	2002-03-26	Konjugater og fremgangsmåter for fremstilling derav, og deres anvendelse for transportering av molekyler via biologiskemembraner
WO2006086357A3 (en)	2007-02-01	Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
WO2002083896A3 (en)	2003-03-13	Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
坂口実	1997	TWO-PERSON HI-LO POKER: STUD AND DRAW, II
AU3359197A (en)	1999-02-08	Game medium and banknote transfer system using air stream
EP1241253A4 (en)	2004-05-19	HUMAN TYROSIN KINASE-HCK BINDING HUMAN PROTEINS AND GENES ENCODING THESE
Mohlenbrock	2000	Leaf Reading in Oahu.
Asgharian et al.	1990	A comparative monomolecular film study of 1, 2-di-O-palmitoyl-3-O-(. alpha.-and. beta.-D-glucopyranosyl)-sn-glycerols [Erratum to document cited in CA111 (11): 92542q]
林明子	2003	Amy and Ken visit grandma
ZA987310B (en)	2000-08-14	Interleukin-18 binding proteins, their preparation and use.
AU7043701A (en)	2001-11-07	A novel polypeptide, dna replication factor c(a1) 37kd human sub-unit 49, and the polynucleotide encoding the polypeptide